Rinostop Extra spray naz. 0.05% fl.

Latin name

Rinostop

Release form

Nasal spray

Packaging

Bottle 15 ml.

pharmachologic effect

Rinostop is a vasoconstrictor for topical use in ENT practice.

Alpha adrenergic agonist.

When applied to mucous membranes, it causes vasoconstriction, as a result of which local hyperemia and edema decrease.

With rhinitis, it facilitates nasal breathing.

Pharmacokinetics

When applied topically, it is practically not absorbed, plasma concentrations are so small that they cannot be determined by modern analytical methods.

Indications

Acute allergic rhinitis, sinusitis, hay fever, otitis media (to reduce swelling of the nasopharyngeal mucosa), preparing the patient for diagnostic procedures in the nasal passages.

Contraindications

Angle-closure glaucoma, atrophic rhinitis, arterial hypertension, tachycardia, severe atherosclerosis, hyperthyroidism, surgery on the meninges (in history), hypersensitivity to xylometazoline.

Application during pregnancy and lactation

During pregnancy and lactation, it should be used only after a careful assessment of the risk-benefit ratio for the mother and the fetus, it is not allowed to exceed the recommended doses.

Structure

1 ml spray contains:

Active substance: xylometazoline.

Method of administration and dosage

Intranasally.

Spraying is performed after removing the safety cap from the sprayer.

The nebulizer is inserted into the nose and, by pressing on its base, spray for 1 second.

For adults and children over the age of 6 years (0.1% spray): one injection from a nebulizer into each nasal passage, usually 3-4 injections per day are enough

should not be applied more than 3 times a day.

For children aged 2 to 6 years (0.05% spray), one spray from a nebulizer into each nasal passage 1 or 2 times a day

should not be applied more than 3 times a day.

Do not use the drug without interruption for more than 3-5 days.

Side effects

With frequent and / or prolonged use: mucosal irritation, burning, tingling, sneezing, dry nasal mucosa, hypersecretion.

Rarely: swelling of the nasal mucosa (more often with prolonged use), palpitations, cardiac arrhythmias, increased blood pressure, headache, vomiting, sleep disorders, visual disturbances.

With long-term use in high doses: depressive state.

Storage conditions

In a dry, dark place at a temperature not exceeding 25 ° C.

Shelf life

3 years

Active substance

Xylometazoline

Name ENG

RHINOSTOP EXTRA

ATX code

oxymetazoline

Dosage

0.05% x 15ml

Structure

Composition per ml: Active ingredient: Oxymetazoline hydrochloride - 0.5 mg.

Excipients: Citric acid monohydrate - 0.609 mg

sodium citrate dihydrate - 3.823 mg

glycerol - 24.348 mg

benzalkonium chloride - 0.15 mg

purified water - up to 1 ml.

Indications

Difficulty in nasal breathing with colds, sinus inflammation, eustachitis, hay fever, allergic rhinitis, congestion and edema of the conjunctiva.

Contraindications

Inflammation of the nasal mucosa without secretion, chronic heart failure, hyperthyroidism, diabetes mellitus, pregnancy, children under 6 years of age (for eye drops), hypersensitivity to oxymetazoline, atrophic rhinitis, lactation period, arrhythmias, severe atherosclerosis, arterial hypertension, chronic renal failure , angle-closure glaucoma.

INN / Active ingredient

oxymetazoline hydrochloride

Storage conditions and periods

At a temperature not higher than 25 degrees.

Expiration date: 2 years

Specifications

Category

Runny nose

Scope of the medicinal product

Ear, Throat, Nose

Release form

Spray

Manufacturer country

Russia

Package quantity, pcs

one

Minimum age from

6 years

Way of introduction

Nasally

Vacation conditions

Without recipe

Volume, ml.

15 ml

Brand name

OTCPharm

The amount of the dosage form in the primary package

15 ml

Primary packaging type

Bottle

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Decongestant - alpha adrenergic agonist

Anatomical and therapeutic characteristics

R01AA05 Oxymetazoline

Dosage form

Nasal spray

The target audience

Children

Expiration date in days

730

Dosage (volume) of the substance in the preparation

0.5 mg

Package weight, g

2

Mode of application

:

Intranasal. < br> < br> Spraying is performed after removing the protective cap from the nebulizer. < br> < br> The nebulizer is inserted into the nose and, pressing on its base, spray for 1 second. < br> < br> For adults and children over the age of 6 years (0.1% spray): one injection from a nebulizer into each nasal passage, usually 3-4 injections per day are enough

should not be applied more than 3 times a day. < br> < br> For children aged 2 to 6 years (0.05% spray), one spray from a nebulizer into each nasal passage 1 or 2 times a day

should not be used more than 3 times a day. < br> Do not use the drug without interruption for more than 3-5 days.